Stock KROS KEROS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
56.39 USD -3.80% Intraday chart for Keros Therapeutics, Inc. +2.17% +41.83%
Mar. 19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT
Mar. 15 Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug MT

Business Summary

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Number of employees: 136

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders
100.0 %
0 nan % 0 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 0 100.0 % -

Managers

Managers TitleAgeSince
Jasbir Seehra CEO
 Chief Executive Officer 68 15-11-30
Keith Regnante DFI
 Director of Finance/CFO 54 20-01-31
Jennifer Lachey CTO
 Chief Tech/Sci/R&D Officer 51 16-06-30
Christopher Rovaldi COO
 Chief Operating Officer 50 22-01-31
Justin Frantz IRC
 Investor Relations Contact - -
Robin Wagner HRO
 Human Resources Officer - 21-05-31
Esther Cho LAW
 General Counsel - 20-03-31

Members of the board

Members of the board TitleAgeSince
Mary Gray BRD
 Director/Board Member 71 20-12-16
Carl Gordon CHM
 Chairman 59 20-02-29
Jasbir Seehra CEO
 Chief Executive Officer 68 15-11-30
Tomer Kariv BRD
 Director/Board Member 62 19-12-31
Ran Nussbaum BRD
 Director/Board Member 51 16-03-31
Nima Farzan BRD
 Director/Board Member 48 20-02-29
Julius Knowles BRD
 Director/Board Member 61 16-03-31
Alpna Seth BRD
 Director/Board Member 60 23-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,067,786 33,773,264 ( 93.64 %) 0 93.64 %

Shareholders

NameEquities%Valuation
Pontifax Management Co. Ltd.
13.30 %
4,787,331 13.30 % 317 M $
Fidelity Management & Research Co. LLC
10.77 %
3,874,204 10.77 % 256 M $
BlackRock Advisors LLC
5.355 %
1,926,812 5.355 % 128 M $
Oppenheimer Asset Management (Alkeon Subfiler)
4.166 %
1,498,907 4.166 % 99 M $
Vanguard Fiduciary Trust Co.
3.980 %
1,432,195 3.980 % 95 M $
Arkin Bio Ventures
3.810 %
1,371,074 3.810 % 91 M $
OrbiMed Advisors Private Equity
3.526 %
1,268,734 3.526 % 84 M $
Braidwell LP
3.110 %
1,118,961 3.110 % 74 M $
Darwin Global Management Ltd.
2.947 %
1,060,427 2.947 % 70 M $
STATE STREET CORPORATION
2.930 %
1,054,367 2.930 % 70 M $

Company contact information

Keros Therapeutics, Inc.

1050 Waltham Street Suite 302

02421, Lexington

+

http://www.kerostx.com
address Keros Therapeutics, Inc.(KROS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Keros Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
58.62 USD
Average target price
88.11 USD
Spread / Average Target
+50.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
KEROS THERAPEUTICS, INC. Stock Keros Therapeutics, Inc.
+41.83% 2.11B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-15.84% 21.2B
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KROS Stock
  4. Company Keros Therapeutics, Inc.